Full Press Release Details
VistaGen Therapeutics Announces Appointment of Ann Cunningham as
Chief Commercial Officer
Ann Cunningham has a proven pharmaceutical commercial track record
of more than 25 years delivering sales, marketing, and global life
cycle product management expertise for many successful branded
product campaigns for large pharmaceutical companies
SAN FRANCISCO, Calif. May 4,
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a
biopharmaceutical company committed to developing a new generation
of medicines with the potential to go beyond the current standard
of care for anxiety, depression, and other central nervous system
( CNS ) disorders, today announced the appointment of
Ann Cunningham as its Chief Commercial Officer. Ms. Cunningham has
a proven pharmaceutical commercial track record of more than 25
years delivering sales, marketing, and global life cycle product
management expertise in roles across several healthcare markets,
including neuropsychiatry and other CNS markets that VistaGen is
pursuing. She has been serving on VistaGen's Board of
Directors ( Board ) since January 2019 and will remain
a member of the Board.
joining our Board, Ann's commercial insight, expertise and
leadership experience has been tremendously helpful in support of
our pre-commercial planning for PH94B, with special emphasis on a
broad range of anxiety markets in the U.S. With the near term
launch of our Phase 3 clinical development program for PH94B, our
investigational product focused on the acute treatment of anxiety
in adults with social anxiety disorder, Ann's appointment as
our Chief Commercial Officer adds considerable strength to the
world-class team we have assembled across all key functional areas
necessary to advance our company through the next phases of our
growth, said Shawn Singh, Chief Executive Officer of
VistaGen. Ann's many
notable accomplishments throughout her distinguished career in the
pharmaceutical industry include leading campaigns
for prominent neuropsychiatric drug treatments in multiple
markets where we believe our investigational products, including
PH94B, have therapeutic and commercial potential. As we look
to transition from clinical development into a commercial growth
mode and steadfastly pursue our mission to create life-changing
medicines to improve mental health and well-being, Ann's
leadership will make a difference.
on the VistaGen Board has allowed me to gain important insight into
the ongoing development of VistaGen's potentially
life-changing CNS product candidates. I am thrilled to expand my
role, join the team full time, and lead the company's
commercial efforts. The company's innovative fast-acting, new
generation CNS drug candidates have exciting potential in large
markets where millions of individuals need novel products that are
safe and effective alternatives to current treatments, said
Cunningham. As VistaGen progresses its late-stage product
candidates, I am excited to ensure that the company will be well
prepared and strategically positioned to build brand awareness for
our lead product candidate, PH94B, and to accelerate its adoption,
as well as that of our other pipeline products, once approved,
across these large target markets.
recently, Ms. Cunningham served as Managing Partner of
Partners, where she guided pharmaceutical and biotechnology
executives in planning and executing successful portfolio
strategies and brand launches by evaluating key business questions
and unique strategies to unlock the full potential of each
organization served. Her experience in the pharmaceutical industry
includes multiple instrumental roles, including Vice President,
Neurodegenerative Disease and Psychiatry at Teva Pharmaceutical
Industries; Senior Director, Global Brand Lead, Rexulti, at Otsuka America
Pharmaceutical; and Senior Director, Global Brand Lead and Sales
Director in multiple therapeutic areas, including Psychiatry, at
Eli Lilly and Company. Ms. Cunningham holds a B.A. in Psychology
from Yale University and an M.B.A. from the University of Michigan,
Stephen M. Ross School of Business.
VistaGen Therapeutics is a biopharmaceutical company committed to
developing and commercializing innovative medicines with the
potential to go beyond the current standard of care for anxiety,
depression, and other CNS disorders. Each of VistaGen's three drug
candidates has a differentiated potential mechanism of action, has
been well-tolerated in all clinical studies to date, and has
therapeutic potential in multiple CNS markets. For more
information, please visit www.VistaGen.com
and connect with VistaGen
on Twitter, LinkedIn, and Facebook.
Forward Looking Statements
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as may, could,
expect, project, outlook,
strategy, intend, plan,
strive, goal, continue,
likely, will, would and
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Such forward-looking
statements are necessarily based upon estimates and assumptions
that, while considered reasonable by us and our management, are
inherently uncertain. Our actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include,
without limitation, risks and uncertainties relating to delays in
launching and/or conducting our planned clinical trials, including
delays due to the impact of the COVID-19 pandemic; fluctuating